These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 36869916)

  • 1. A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
    de Geus SWL; Sachs TE
    Ann Surg Oncol; 2023 Jun; 30(6):3427-3436. PubMed ID: 36869916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
    Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
    Yamaguchi J; Yokoyama Y; Fujii T; Yamada S; Takami H; Kawashima H; Ohno E; Ishikawa T; Maeda O; Ogawa H; Kodera Y; Nagino M; Ebata T
    Ann Surg; 2022 Jun; 275(6):1043-1049. PubMed ID: 35258510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
    Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
    Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
    Brown ZJ; Cloyd JM
    J Surg Oncol; 2021 May; 123(6):1432-1440. PubMed ID: 33831253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized Pancreatic Cancer: Multidisciplinary Management.
    Coveler AL; Herman JM; Simeone DM; Chiorean EG
    Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
    Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
    Conroy T; Gavoille C; Samalin E; Ychou M; Ducreux M
    Curr Oncol Rep; 2013 Apr; 15(2):182-9. PubMed ID: 23341367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
    Conroy T; Hammel P; Hebbar M; Ben Abdelghani M; Wei AC; Raoul JL; Choné L; Francois E; Artru P; Biagi JJ; Lecomte T; Assenat E; Faroux R; Ychou M; Volet J; Sauvanet A; Breysacher G; Di Fiore F; Cripps C; Kavan P; Texereau P; Bouhier-Leporrier K; Khemissa-Akouz F; Legoux JL; Juzyna B; Gourgou S; O'Callaghan CJ; Jouffroy-Zeller C; Rat P; Malka D; Castan F; Bachet JB;
    N Engl J Med; 2018 Dec; 379(25):2395-2406. PubMed ID: 30575490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.
    Uson Junior PLS; Dias E Silva D; de Castro NM; da Silva Victor E; Rother ET; Araújo SEA; Borad MJ; Moura F
    ESMO Open; 2023 Feb; 8(1):100771. PubMed ID: 36638709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy.
    Irfan A; Rose JB; Wang TN; Vickers SM; Dudeja V; Gbolahan O; Reddy S
    Pancreas; 2022 Jan; 51(1):100-105. PubMed ID: 35195602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
    Yang A; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):585-601. PubMed ID: 25686370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.